Drugmaker AbbVie to acquire Capstan Therapeutics for over $2 billion Health July 1, 2025 AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.